ENDOCEUTICS: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
ENDOCEUTICS
Largest movements
- Receivables within one year -€997,439
down €997,439 (-39.5%), from €2.5m to €1.5m
of which Trade receivables: -€845,644
- Stocks and contracts -€441,756
down €441,756 (-25.2%), from €1.7m to €1.3m
- Cash +€189,653
up €189,653 (+45.0%), from €421,485 to €611,138
mainly Receivables within one year (+€997,439) and Stocks and contracts (+€441,756)
- Trade debts -€1.9m
down €1.9m (-59.2%), from €3.2m to €1.3m
- Profit (loss) carried forward +€348,842
up €348,842, from -€175,599 to €173,243
- Other debts +€300,197
up €300,197 (+19.5%), from €1.5m to €1.8m
- Gross operating margin +€292,177
up €292,177 (+237.2%), from €123,176 to €415,353
- Taxes +€63,065
new in 2025: €63,065
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €4,705,675 | €3,453,444 | -€1.3m | -26.6% |
| Current assets | 29/58 | €4,705,675 | €3,453,444 | -€1.3m | -26.6% |
| Stocks and contracts in progress | 3 | €1,749,779 | €1,308,023 | -€441,756 | -25.2% |
| Stocks | 30/36 | €1,749,779 | €1,308,023 | -€441,756 | -25.2% |
| Amounts receivable within one year | 40/41 | €2,526,629 | €1,529,191 | -€997,439 | -39.5% |
| Trade receivables | 40 | €2,282,141 | €1,436,497 | -€845,644 | -37.1% |
| Other amounts receivable | 41 | €244,489 | €92,694 | -€151,795 | -62.1% |
| Cash at bank and in hand | 54/58 | €421,485 | €611,138 | +€189,653 | +45.0% |
| Deferred charges and accrued income | 490/1 | €7,782 | €5,092 | -€2,690 | -34.6% |
| Total equity and liabilities | 10/49 | €4,705,675 | €3,453,444 | -€1.3m | -26.6% |
| Equity | 10/15 | -€114,099 | €234,743 | +€348,842 | |
| Contributions | 10/11 | €61,500 | €61,500 | = | 0.0% |
| Capital | 10 | €61,500 | €61,500 | = | 0.0% |
| Issued capital | 100 | €61,500 | €61,500 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€175,599 | €173,243 | +€348,842 | |
| Amounts payable | 17/49 | €4,819,774 | €3,218,701 | -€1.6m | -33.2% |
| Amounts payable within one year | 42/48 | €4,819,774 | €3,215,701 | -€1.6m | -33.3% |
| Trade debts | 44 | €3,207,708 | €1,309,514 | -€1.9m | -59.2% |
| Suppliers | 440/4 | €3,207,708 | €1,309,514 | -€1.9m | -59.2% |
| Taxes, remuneration and social security | 45 | €69,141 | €63,065 | -€6,077 | -8.8% |
| Taxes | 450/3 | €69,141 | €63,065 | -€6,077 | -8.8% |
| Other amounts payable | 47/48 | €1,542,925 | €1,843,122 | +€300,197 | +19.5% |
| Accrued charges and deferred income | 492/3 | - | €3,000 | +€3,000 | |
| Other operating charges | 640/8 | - | €1,425 | +€1,425 | |
| Gross operating margin | 9900 | €123,176 | €415,353 | +€292,177 | +237.2% |
| Operating profit (loss) | 9901 | €123,176 | €413,927 | +€290,752 | +236.0% |
| Financial income | 75/76B | €55 | €315 | +€259 | +468.7% |
| Recurring financial income | 75 | €55 | €315 | +€259 | +468.7% |
| Financial charges | 65/66B | €3,751 | €2,335 | -€1,415 | -37.7% |
| Recurring financial charges | 65 | €3,751 | €2,335 | -€1,415 | -37.7% |
| Profit (loss) for the period before taxes | 9903 | €119,480 | €411,907 | +€292,426 | +244.7% |
| Income taxes | 67/77 | - | €63,065 | +€63,065 | |
| Profit (loss) for the period | 9904 | €119,480 | €348,842 | +€229,362 | +192.0% |
| Profit (loss) for the period to be appropriated | 9905 | €119,480 | €348,842 | +€229,362 | +192.0% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 11 October 2026 via checked.be.